- AI
- Molecular Imaging
- CT
- X-Ray
- Ultrasound
- MRI
- Facility Management
- Mammography
DC DiagnostiCare acquires clinics
Imaging services firm DC DiagnostiCare of Edmonton, Alberta, announced last month that it has completed the purchase of four imaging clinic companies that provide service in Manitoba and Ontario. The companies include C&T Diagnostic Imaging of
Imaging services firm DC DiagnostiCare of Edmonton, Alberta, announced last month that it has completed the purchase of four imaging clinic companies that provide service in Manitoba and Ontario. The companies include C&T Diagnostic Imaging of Ottawa, Metro Clinics of Winnipeg, Vid-X Limited of Toronto, and Central Ultrasound of southern Ontario. The purchases will increase DC DiagnostiCares gross revenue by $5.3 million and represent a concerted acquisition push for the final months of 1998.
DC DiagnostiCare has acquired more than 60 nonhospital-based medical imaging clinics across Canada since the beginning of the year. It now owns 94 clinics throughout Alberta, Manitoba, Ontario, and British Columbia (SCAN 6/10/98). The company plans to continue to focus its acquisition efforts on the more than 1200 nonhospital-based clinics across Canada. DC DiagnostiCare finalized its acquisition of North American Imaging last month, its first U.S. purchase.
Can Generative AI Facilitate Simulated Contrast Enhancement for Prostate MRI?
January 14th 2025Deep learning synthesis of contrast-enhanced MRI from non-contrast prostate MRI sequences provided an average multiscale structural similarity index of 70 percent with actual contrast-enhanced prostate MRI in external validation testing from newly published research.
Can MRI Have an Impact with Fertility-Sparing Treatments for Endometrial and Cervical Cancers?
January 9th 2025In a literature review that includes insights from recently issued guidelines from multiple European medical societies, researchers discuss the role of magnetic resonance imaging (MRI) in facilitating appropriate patient selection for fertility-sparing treatments to address early-stage endometrial and cervical cancer.
